Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;6(4):322-8.
doi: 10.2174/157015908787386069.

Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate

Affiliations

Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate

Veronika Engert et al. Curr Neuropharmacol. 2008 Dec.

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is a childhood psychiatric condition characterized by severe impulsiveness, inattention and overactivity. Methylphenidate (MPH), a psychostimulant affecting both the dopaminergic and the noradrenergic systems, is one of the most frequently prescribed treatments for ADHD. Despite the widespread use of MPH and its proven effectiveness, its precise neurochemical mechanisms of action are under debate. For the most part, MPH's influence on subcortical dopamine neurotransmission is thought to play a crucial role in its behavioral and cognitive effects. In their hypothesis of biphasic MPH action, Seeman and Madras [42, 43] suggest that therapeutic doses of MPH elevate tonic dopamine while inhibiting phasic transmitter release in subcortical structures, leading to reduced postsynaptic receptor stimulation and psychomotor activation in response to salient stimuli. Volkow and colleagues [56] suggest that by amplifying a weak striatal dopamine signal, MPH increases the perception of a stimulus or task as salient. The enhanced interest for the task is thought to increase attention and improve performance. Recent animal studies have however shown that when administered at doses producing clinically relevant drug plasma levels and enhancing cognitive function, MPH preferentially activates dopamine and noradrenaline efflux within the prefrontal cortex relative to the subcortical structures [5]. Overall, we suggest that the delineated theories of MPH therapeutic action should not be discussed as exclusive. Studies are outlined that allow integrating the different findings and models.

Keywords: ADHD; dopamine; methylphenidate; noradrenaline; prefrontal.; subcortical.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Means and standard errors for the interaction effect of reward and treatment on performance. Post-hoc simple main effects analyses revealed that after placebo as compared to methylphenidate (MPH) administration, a) the number of total responses (p=.02), b) the number of correct responses (p<.001) and c) the success rate (p<.001) were increased with reward. MPH thus inhibited a reward-induced increase in behavioral activity and performance improvement **p<.01.

References

    1. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 1990;525:36–44. - PubMed
    1. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav. Brain Funct. 2005;1:2. - PMC - PubMed
    1. Barkley RA, Grodzinsky G, DuPaul GJ. Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J. Abnorm. Child Psychol. 1992;20:163–188. - PubMed
    1. Berridge CW. Noradrenergic modulation of arousal. Brain Res. Rev. 2008;58:1–17. - PMC - PubMed
    1. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses That Enhance Cognitive Function. Biol. Psychiatry. 2006;60:1111–1120. - PubMed